Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer

Joachim von Pawel, David R Spigel, Thomas Ervin, György Losonczy, Fabrice Barlesi, Erzsébet Juhász, Maria Anderson, Bruce McCall, Eric Wakshull, Priti Hegde, Weilan Ye, Daniel Chen, Ilsung Chang, Ina Rhee, Martin Reck, Joachim von Pawel, David R Spigel, Thomas Ervin, György Losonczy, Fabrice Barlesi, Erzsébet Juhász, Maria Anderson, Bruce McCall, Eric Wakshull, Priti Hegde, Weilan Ye, Daniel Chen, Ilsung Chang, Ina Rhee, Martin Reck

Abstract

Lessons learned: The lack of efficacy associated with anti-EGFL7 combined with standard bevacizumab and chemotherapy in this phase II trial in non-small cell lung carcinoma is consistent with the lack of benefit observed in colorectal carcinoma, highlighting the challenge of enhancing the efficacy of VEGF inhibition in unselected populations.Future efforts with agents like anti-EGFL7 should be guided by advances in pharmacodynamic and predictive biomarker development for antiangiogenic agents.

Background: Epidermal growth factor-like domain 7 (EGFL7) is an extracellular matrix-associated protein that is upregulated during angiogenesis and supports endothelial cell survival. This phase II trial evaluated the efficacy of the anti-EGFL7 antibody, parsatuzumab, in combination with bevacizumab plus platinum-based therapy for advanced or recurrent nonsquamous non-small cell lung cancer (NS-NSCLC).

Methods: Patients (n = 104) were randomized to either placebo or parsatuzumab (600 mg) in combination with bevacizumab (15 mg/kg) and carboplatin/paclitaxel, administered on day 1 of each 21-day cycle. Carboplatin and paclitaxel were administered for up to six cycles. Bevacizumab and parsatuzumab/placebo were administered for a maximum of 24 months.

Results: The progression-free survival (PFS) hazard ratio (HR) was 1.7 (95% confidence interval [CI], 1.0-2.8; p = .047). The median PFS was 6.7 months for the parsatuzumab arm versus 8.1 months for the placebo arm. The hazard ratio for overall survival (OS) was 1.1 (95% CI, 0.5-2.2; p = .847). The objective response rate (ORR) was 29% in the parsatuzumab arm and 56% in the placebo arm. Overall safety and tolerability were consistent with the established toxicity profile of bevacizumab.

Conclusion: There was no evidence of efficacy for the addition of parsatuzumab to the combination of bevacizumab and chemotherapy for first-line NS-NSCLC.

Trial registration: ClinicalTrials.gov NCT01366131.

©AlphaMed Press; the data published online to support this summary is the property of the authors.

Figures

Figure 1.
Figure 1.
Kaplan‐Meier estimates of progression‐free survival. Note: + = censored value. Abbreviations: CI, confidence interval; parsatuzumab, paclitaxel + carboplatin + bevacizumab + MEGF0444A; placebo, paclitaxel + carboplatin + bevacizumab.
Figure 2.
Figure 2.
Study scheme. Abbreviations: AUC 6, area under curve of 6 mg • min/ml (Calvert formula); NSCLC, non‐small cell lung cancer; PD, progressive disease; PS, performance status; q21d, every 21 days.

References

    1. Parker LH, Schmidt M, Jin SW et al. The endothelial‐cell‐derived secreted factor EGFL7 regulates vascular tube formation. Nature 2004;428:754–758.
    1. Johnson L, Huseni M, Smyczek T et al. Anti‐EGFL7 antibodies enhance stress‐induced endothelial cell death and anti‐VEGF efficacy. J Clin Invest 2013;123:3997–4009.
    1. Naumovski L, Gordon MS, Munster PN et al. A phase 1b dose‐escalation study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMab) anti‐EGFL7 (MEGF0444A) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors. J Clin Oncol 2011;29(suppl 15):2514a.
    1. Garcia‐Carbonero R, van Cutsem E, Rivera F et al. Randomized phase II trial of parsatuzumab (anti‐EGFL7) or placebo in combination with FOLFOX and bevacizumab for first‐line metastatic colorectal cancer. The Oncologist 2017;22:375–e30.
    1. Schoenfeld D. The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika 1981;68:316–319.
    1. Reinmuth N, Heigener D, Reck M. Novel angiogenesis inhibitors in nonsmall cell lung cancer. Curr Opin Oncol 2015;27:79–86.
    1. Sandler A, Gray R, Perry MC et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small‐cell lung cancer. N Engl J Med 2006;355:2542–2550.
    1. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first‐line therapy for nonsquamous non‐small‐cell lung cancer: AVAil. J Clin Oncol 2009;27:1227–1234.
    1. Ranieri G, Patruno R, Ruggieri E et al. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: From the biology to the clinic. Curr Med Chem 2006;13:1845–1857.
    1. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF‐specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145–147.
    1. Schmidt M, Paes K, De Maziere A et al. EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution. Development 2007;134:2913–2923.
    1. Xu D, Perez RE, Ekekezie II et al. Epidermal growth factor‐like domain 7 protects endothelial cells from hyperoxia‐induced cell death. Am J Physiol Lung Cell Mol Physiol 2008;294:L17–L23.
    1. Soncin F, Mattot V, Lionneton F et al. VE‐statin, an endothelial repressor of smooth muscle cell migration. EMBO J 2003;22:5700–5711.
    1. Fitch MJ, Campagnolo L, Kuhnert F et al. Egfl7, a novel epidermal growth factor‐domain gene expressed in endothelial cells. Dev Dyn 2004;230:316–324.
    1. Nichol D, Stuhlmann H. EGFL7: A unique angiogenic signaling factor in vascular development and disease. Blood 2012;119:1345–1352.
    1. Campagnolo L, Leahy A, Chitnis S et al. EGFL7 is a chemoattractant for endothelial cells and is up‐regulated in angiogenesis and arterial injury. Am J Pathol 2005;167:275–284.
    1. Yeung S, Smyczek T, Cheng J et al. Abstract 3295: Inhibiting vascular morphogenesis in tumors: EGFL7 as a novel therapeutic target. Cancer Research 2011;71:3295a.
    1. Inai T, Mancuso M, Hashizume H et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35–52.
    1. Mancuso MR, Davis R, Norberg SM et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610–2621.
    1. Vosseler S, Mirancea N, Bohlen P et al. Angiogenesis inhibition by vascular endothelial growth factor receptor‐2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 2005;65:1294–1305.
    1. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005;15:102–111.
    1. Patel JD, Socinski MA, Garon EB et al. PointBreak: A randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIb or IV nonsquamous non‐small‐cell lung cancer. J Clin Oncol 2013;31:4349–4357.
    1. Hapani S, Sher A, Chu D et al. Increased risk of serious hemorrhage with bevacizumab in cancer patients: A meta‐analysis. Oncology 2010;79:27–38.
    1. Mok T, Gorbunova V, Juhasz E et al. A correlative biomarker analysis of the combination of bevacizumab and carboplatin‐based chemotherapy for advanced nonsquamous non‐small‐cell lung cancer: Results of the phase II randomized ABIGAIL study (BO21015). J Thorac Oncol 2014;9:848–855.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する